Surgical research in urology and renal trasplantation

Search for publications

Only original articles, editorials, guidelines.

  • Fiala O, Buti S, Fujita K, de Liaño AG, Fukuokaya W, Kimura T, Yanagisawa T, Giannatempo P, Angel M, Mennitto A, Molina-Cerrillo J, Bourlon MT, Soares A, Takeshita H, Calabrò F, Ortega C, Kucharz J, Milella M, Seront E, Park SH, Tural D, Benedetti G, Ürün Y, Battelli N, Melichar B, Poprach A, Buchler T, Kopecký J, Conteduca V, Monteiro FSM, Massari F, Gupta S, Santoni M.

    Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2(EV) study.

    CLINICAL & EXPERIMENTAL METASTASIS . 42(2): 18-18.

    [doi:10.1007/s10585-025-10335-4]

  • Del Olmo-García M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, Gomez M, Palma Milla S, Suarez L, Bellver M, Alonso V, Serrano R, Valdés N, Melian M, Febrero B, Sampedro-Nuñez MA, Biarnes J, Díaz-Pérez JÁ, Molina-Cerrillo J, Lopez C, Martínez Olmos MÁ, Merino-Torres JF, Capdevila J, Argente Pla M.

    Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.

    ONCOLOGIST . 30(2): .

    [doi:10.1093/oncolo/oyae343]

  • Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M.

    Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.

    CANCER MEDICINE . 14(4): .

    [doi:10.1002/cam4.70479]

  • Tresh AS, Del Giudice F, Li S, Basran S, De Berardinis E, Carino D, Santarelli V, Rocco B, Shighinolfi MC, Mayr R, Ferro M, Autorino R, Bignante G, Crocetto F, Barone B, Pichler R, Subiela JD, Velasco JC, Moschini M, Mari A, Gallioli A, Soria F, Albisinni S, Krajewski W, Laszkiewicz J, Nowak L, Szydelko T, Challacombe B, Nair R, Chung BI.

    The impact of preoperative venous thromboembolism on patients undergoing TURBT: Perioperative outcomes and healthcare costs from US insurance claims data.

    Bjui Compass . 6(1): .

    [doi:10.1002/bco2.481]

  • Rodríguez-Monsalve M, Durán-Poveda M, Gómez Dos Santos V, Burgos Revilla J, García-Criado E, Prieto D, Gil de Miguel Á, Sáenz-Medina J.

    Impact of Obesity on Hospitalization Burden of Urolithiasis in Spain Between 1997 and 2021.

    Journal Of Clinical Medicine . 14(2): .

    [doi:10.3390/jcm14020381]

  • Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, Monteiro FSM, Cattrini C, Landmesser J, Messina C, Zgura A, Rebuzzi SE, Soares A, Carrozza F, Ansari J, Grillone F, Küronya Z, Incorvaia L, Bhuva D, Ortega C, Nasso C, Kanesvaran R, Zampiva I, Porta C, Buti S, Santoni M.

    First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(2): 65-65.

    [doi:10.1007/s00262-024-03897-x]

  • Pichler R, Fritz J, Maier S, Hassler MR, Krauter J, D Andrea D, Laukhtina E, Gust K, Mori K, Tully KH, Niedersuess-Beke D, Korber L, Spiegelberg JA, Bauernhofer T, Subiela JD, Mayr R, Kronbichler A, Moschini M, Teoh J, Pradere B, Shariat SF, Ulmer H, Mertens LS.

    Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(1): 30-30.

    [doi:10.1007/s00262-024-03871-7]

  • Ruz-Caracuel I, Pedraza-Arevalo S, Alonso-Gordoa T, Molina-Cerrillo J, Earl J, Sainz B Jr.

    Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.

    Endocrine Oncology (bristol, England) . 4(1): .

    [doi:10.1530/EO-24-0006]

  • Artiles Medina A, Subiela Henríquez JD, Muriel García A, Mínguez Ojeda C, Sánchez González Á, DE LA Parra Sánchez I, López Curtis D, Gómez Dos Santos V, Jiménez Cidre MÁ, Burgos Revilla FJ.

    Urinary tract infection as a leading cause of morbidity after radical cystectomy: unveiling microbiological patterns and risk factors.

    Minerva Urology And Nephrology . : .

    [doi:10.23736/S2724-6051.24.06171-8]

  • Coca-Perez A, Rivero-Jimenez N, Lopez-Menendez J, Boteanu AL, Moreno-Mata N.

    Talc-induced pericardial granulomatosis after recurrent pleurodesis: a rare cause of incessant pericarditis-case report.

    EUROPEAN HEART JOURNAL-CASE REPORTS . 8(12): .

    [doi:10.1093/ehjcr/ytae603]

  • Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, Pichler M, Vitale MG, Fiala O, Roviello G, Kopp RM, Carrozza F, Pichler R, Grillone F, Calabuig EP, Zeppellini A, Küronya Z, Galli L, Facchini G, Sunela K, Mosca A, Molina-Cerrillo J, Spinelli GP, Ansari J, Scala A, Mollica V, Grande E, Buti S, Kanesvaran R, Zakopoulou R, Bamias A, Rizzo M, Massari F, Iacovelli R, Santoni M.

    Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).

    INTERNATIONAL JOURNAL OF CANCER . 155(11): 2036-2046.

    [doi:10.1002/ijc.35141]

  • Medina, Alberto Artiles, Ojeda, Cesar Minguez, Henriquez, Jose Daniel Subiela, Garcia, Alfonso Muriel, Gonzalez, alvaro Sanchez, Alcaraz, Marina Mata, Burgos, Jennifer Brasero, Borau, Pablo Gajate, Dos Santos, Victoria Gomez, Cidre, Miguel Angel Jimenez, Revilla, Francisco Javier Burgos.

    Nomograms to Appraise The Risk of Chronic Kidney Disease After Radical Cystectomy: Shifting The Focus to Prevention

    CLINICAL GENITOURINARY CANCER . 22(6): 102205-102205.

    [doi:10.1016/j.clgc.2024.102205]

  • Staehler, Michael, Basso, Umberto, Eymard, Jean-Christophe, Barthelemy, Philippe, Bigot, Pierre, Laramas, Mathieu, Rink, Michael, Suarez, Cristina, Guillot, Aline, Bedke, Jens, Hamberg, Paul, De Vivo, Rocco, Gajate, Pablo, Lazaro-Quintela, Martin, Rastogi, Priti, Perrot, Valerie, Qvick, Bryan, Dutailly, Pascale, Verzoni, Elena, Procopio, Giuseppe.

    A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).

    CLINICAL GENITOURINARY CANCER . 23(1): 102285-102285.

    [doi:10.1016/j.clgc.2024.102285]

  • Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Laukhtina E, Rajwa P, Quhal F, Pradere B, Fukuokaya W, Iwatani K, Afferi L, Marcq G, Mertens LS, Gallioli A, Tully KH, Caño-Velasco J, Subiela JD, Abu-Ghanem Y, Grobet-Jeandin E, Del Giudice F, Pichler R, Teoh JY, Moschini M, Krajewski W, Miki J, Shariat SF, Kimura T.

    Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.

    TARGETED ONCOLOGY . : .

    [doi:10.1007/s11523-024-01114-4]

  • Amat-Santos IJ, García-Gómez M, Avanzas P, Jiménez-Diaz V, Alonso-Briales JH, de la Torre Hernández JM, Sanz-Sánchez J, Diarte-de Miguel JA, Sánchez-Recalde Á, Nombela-Franco L, Jiménez-Mazuecos J, Serra V, Nogales-Asensio JM, García-Blas S, Gómez-Menchero A, Del Valle R, Mayor Déniz C, Al Houssaini W, Veiga-Fernández G, Diez-Gil JL, Jimeno Sánchez J, López Menéndez J, Fernández-Cordón C, Gómez-Salvador I, Bustamante-Munguira J, Kedhi E, San Román JA.

    Surgical vs Transcatheter Treatment in Patients With Coronary Artery Disease and Severe Aortic Stenosis.

    JACC-CARDIOVASCULAR INTERVENTIONS . 17(21): 2472-2485. Number of citations: 1

    [doi:10.1016/j.jcin.2024.09.003]

  • Faba OR, Boissier R, Budde K, Figueiredo A, Hevia V, García EL, Regele H, Zakri RH, Olsburgh J, Bezuidenhout C, Breda A.

    European Association of Urology Guidelines on Renal Transplantation: Update 2024.

    European Urology Focus . : .

    [doi:10.1016/j.euf.2024.10.010]

  • Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M.

    Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2(EV) Study.

    TARGETED ONCOLOGY . 19(6): 905-915.

    [doi:10.1007/s11523-024-01099-0]

  • Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE.

    Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.

    JAMA Oncology . 10(11): 1565-1570.

    [doi:10.1001/jamaoncol.2024.3900]